Preliminary efficacy, feasibility and safety of intra-umbilical oxytocin to reduce the time to placental delivery at caesarean section: an exploratory randomized trial

What Was Tested

The paper reports a study of Oxytocin, published as a randomized controlled trial.

Delayed placental separation either after vaginal birth or caesarean birth is an important cause of postpartum haemorrhage, among other causes such as uterine atony.

Who Took Part

The abstract describes 66 women taking part.

PubMed tags the participants as women only.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The women were allocated by chance, so the Oxytocin group and the comparison group should start out alike.

Blinding on both sides kept the women and researchers unaware of who received Oxytocin.

The comparison arm used a placebo, so changes seen with Oxytocin could be set against what happens without it.

A double-blind, placebo-controlled, exploratory randomized clinical trial was conducted at a tertiary hospital in the Eastern Cape Province, South Africa.

Data were analysed using Epi Info and RevMan software.

Feasibility was determined by observing the successful insertion of the catheter and injection of the solution.

Safety was evaluated by investigating adverse effects of the procedure.

What Was Measured

The subject headings attached to it are Oxytocin, Cesarean Section, Oxytocics, Feasibility Studies and Placenta.

The authors tagged it with the keywords Caesarean section, intra-umbilical oxytocin and postpartum haemorrhage.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Oxytocin in 66 women.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (African health sciences), a journal based in Uganda.

More context: the Oxytocin compound page, all human trials.